|0.57|| -0.02 / -3.39%|
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
|Jeffrey Lucero Riley||President, Chief Executive Officer & Director|
|Steven A. Shallcross||Chief Financial Officer, Secretary & Treasurer|
|Michael Kaleko||Senior Vice President-Research & Development|
|Joseph Sliman||Chief Medical Officer|
|Klaus Gottlieb||Vice President-Clinical & Regulatory Affairs|